Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jop P Mostert

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 23, 2013
Cerebral white matter blood flow and energy metabolism in multiple sclerosisChristel Steen, Miguel D'haeseleer, Johannes M Hoogduin, et al.
Neurology|August 4, 2017
Five cases of malignant melanoma during fingolimod treatment in Dutch patients with MSJoep Killestein, Cyra E Leurs, Erwin L J Hoogervorst, et al.
Contemporary Clinical Trials|September 4, 2025
Evaluating the effect of cannabidiol on sleep quality in patients with multiple sclerosis using 15 aggregated N-of-1 trials: A study protocolBo A D F Saals, Renger F Witkamp, Anne Claire B van Orten-Luiten, et al.
Neurology|July 22, 2020
Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trialZoé L E van Kempen, Erwin L J Hoogervorst, Mike P Wattjes, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|July 20, 2019
Cognitive functioning as a predictor of employment status in relapsing-remitting multiple sclerosis: a 2-year longitudinal studyDennis A M van Gorp, Karin van der Hiele, Marco A P Heerings, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 4, 2024
Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patientsAlyssa A Toorop, Mark Hj Wessels, Lynn Boonkamp, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 14, 2023
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)Alyssa A Toorop, Zoë Ygj van Lierop, Liza My Gelissen, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 23, 2013
Cerebral white matter blood flow and energy metabolism in multiple sclerosisChristel Steen, Miguel D'haeseleer, Johannes M Hoogduin, et al.
Neurology|August 4, 2017
Five cases of malignant melanoma during fingolimod treatment in Dutch patients with MSJoep Killestein, Cyra E Leurs, Erwin L J Hoogervorst, et al.
Contemporary Clinical Trials|September 4, 2025
Evaluating the effect of cannabidiol on sleep quality in patients with multiple sclerosis using 15 aggregated N-of-1 trials: A study protocolBo A D F Saals, Renger F Witkamp, Anne Claire B van Orten-Luiten, et al.
Neurology|July 22, 2020
Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trialZoé L E van Kempen, Erwin L J Hoogervorst, Mike P Wattjes, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|July 20, 2019
Cognitive functioning as a predictor of employment status in relapsing-remitting multiple sclerosis: a 2-year longitudinal studyDennis A M van Gorp, Karin van der Hiele, Marco A P Heerings, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 4, 2024
Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patientsAlyssa A Toorop, Mark Hj Wessels, Lynn Boonkamp, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 14, 2023
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)Alyssa A Toorop, Zoë Ygj van Lierop, Liza My Gelissen, et al.
Pageof 3